Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Xenon Pharmaceuticals Inc

XP0
Current price
39.8 EUR +1.2 EUR (+3.11%)
Last closed 42.62 USD
ISIN CA98420N1050
Sector Healthcare
Industry Biotechnology
Exchange Stuttgart Exchange
Capitalization 3 122 254 848 USD
Yield for 12 month +24.03 %
1Y
3Y
5Y
10Y
15Y
XP0
21.11.2021 - 28.11.2021

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. Address: 3650 Gilmore Way, Burnaby, BC, Canada, V5G 4W8

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

57.32 USD

P/E ratio

Dividend Yield

Current Year

Last Year

+9 434 000 USD

Current Quarter

Last Quarter

Current Year

-167 512 000 USD

Last Year

+9 434 000 USD

Current Quarter

-659 000 USD

Last Quarter

-599 000 USD

Key Figures XP0

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -233 680 992 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -18.92 %
PEG Ratio -0.06
Return On Equity TTM -26.71 %
Wall Street Target Price 57.32 USD
Revenue TTM
Book Value 11.16 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -100 %
Dividend Yield
Gross Profit TTM -96 333 000 USD
Earnings per share -2.73 USD
Diluted Eps TTM -2.73 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics XP0

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History XP0

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation XP0

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 10874.6335
Price Sales TTM 181.4446
Enterprise Value EBITDA -11.8089
Price Book MRQ 3.6991

Financials XP0

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators XP0

For 52 weeks

27.99 USD 50.99 USD
50 Day MA 39.88 USD
Shares Short Prior Month 3 595 318
200 Day MA 42.04 USD
Short Ratio 10.62
Shares Short 3 301 156
Short Percent 4.39 %